spacer
home > epc > winter 2009 > the key to tqt
PUBLICATIONS
European Pharmaceutical Contractor

The Key to TQT

 

During the early stages of clinical development, the ability of new drugs to delay cardiac repolarisation is of key concern. As a result, dedicated clinical pharmacology studies designed to examine the effects on cardiac repolarisation have become increasingly important to the pharmaceutical industry and are today an integral component in the development of new chemical entities (NCEs) and ongoing drug development programmes for new drug submissions. These studies, known as ‘thorough QT/QTc studies’ (TQT), are now so significant that they can determine the course, and indeed the viability, of an entire drug development programme.

The first governing body to issue guidance in the form of a ‘Points to Consider’ document was the European Agency for the Evaluation of Medicinal Products (EMEA) in 1997. More recent regulatory guidance for TQT analysis has raised new considerations and challenges when designing drug development programmes. The successful completion of a TQT study in the digital ECG era is highly dependent upon superior technology and efficient, predefined processes to properly manage ECGs.

THE KEY ELEMENTS TO A SUCCESSFUL TQT STUDY

TQT studies came to prominence in order to give an early indication of QT prolongation in human subjects, as a signal of the potential of Torsades de Pointes (TdP). Through a reduction in cost by an appropriate and equal emphasis on the three key elements of these studies, TQT studies could more regularly be conducted at a much earlier stage of development of a NCE. If this were to occur, the resulting signal, positive or negative, will help shape the further development of a compound, rather than just being a regulatory necessity. The key elements to achieve a successful TQT study are:


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer

Asif Naseem has worked as a Medical Writer in both the medical communication agency and clinical research organisation settings. He has been involved in academic science and pharmacology in particular for over eight years. Asif currently specialises in generating clinical study protocols, clinical study reports and related material for a number of Phase I clinical trials performed at Richmond Pharmacology. Additionally, he is involved in the development and generation of posters for conferences and primary manuscripts for publication.

Keith Berelowitz has worked in both the academic and commercial environment of scientific research for more than 10 years. As Director of Operations for Richmond Pharmacology, Keith is responsible for coordinating the integration of employees and processes related to the efficient conduct of early phase clinical trials. Before taking on his current role, Keith was responsible for the recruitment of healthy and patient volunteers for early phase clinical trials (including TQT studies) at Richmond Pharmacology.

Dr Jörg Täubel is a medical practitioner and Managing Director of Richmond Pharmacology, which he co-founded in 2001. He has worked in pharmacology for nearly 20 years and during that time has conducted more than 400 early phase studies in patient, paediatric and healthy volunteers. His experience ranges from first-in-human to proof of concept studies. His particular interests are in cardiology, neurology, gastroenterology, bridging and thorough QT studies.

spacer
Asif Naseem
spacer
spacer
spacer
Keith Berelowitz
spacer
spacer
spacer
Jörg Täubel
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Arcis Biotechnology appointments Professor Steve Howell as Non-Executive Chairman

Daresbury, UK, 24 July 2019: Arcis Biotechnology (“Arcis”), the nucleic acid sample preparation solution provider, today announced it has appointed Professor Steve Howell as Non-Executive Chairman of its Board of Directors. Steve takes over the position from Paul Foulger, who was serving as Chairman on an interim basis on behalf of the Board.
More info >>

White Papers

Advanced BioDesign Outlines Solutions

Advanced BioDesign

Launching an immunisation programme is an important experimental step that needs care. With Advanced BioDesign, clients may develop and produce antibodies according to customers' specific needs. The company offers: real support and advice from a dedicated team all along your project; large and modern SPF animal facility; ethical treatment of animals. The evaluation of a project is free-of-charge and with no obligation. Dedicated project managers will work with clients from the beginning to the end of a custom antibody project to ensure the highest level of quality and service.
More info >>

 
Industry Events

CPhI Worldwide

5-7 November 2019, Frankfurt, Germany

Join the World's Largest Pharma Event As it Celebrates its 30th Anniversary! Taking place from 5-7 November 2019 in Frankfurt, Germany, the event will bring together more than 45,000 visiting pharma professionals from around the globe and over 2,500 exhibiting pharma companies from every stage of the pharmaceutical supply chain - from ingredients and machinery to outsourcing services, packaging and more!
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement